Ketogenic Interventions for PKD
A comprehensive overview of the research on ketogenic diet, ketone supplements, and metabolic interventions for Polycystic Kidney Disease.
KETO-ADPKD Trial
Completed 2023 — First RCT of keto diet in ADPKD
KetoCitra / Ren-Nu
Observational data — 103 patients, eGFR +6.3%
Preclinical Evidence
BHB + Citrate synergy demonstrated in animal models
Scientific Rationale
PKD cysts rely heavily on glucose for growth through a metabolic shift similar to the Warburg effect in cancer cells. A ketogenic state may counteract cyst growth through multiple mechanisms:
- Beta-hydroxybutyrate (BHB) — the primary ketone body — may directly inhibit cyst cell proliferation through signaling pathways independent of its role as fuel
- AMPK activation — ketosis activates AMP-activated protein kinase, which inhibits mTOR signaling (a key driver of cyst growth)
- Glucose deprivation — reducing glucose availability may "starve" glucose-dependent cyst cells
- CFTR inhibition — AMPK activation inhibits chloride secretion through CFTR channels, reducing cyst fluid accumulation
Initial preclinical work by Thomas Weimbs' lab at UCSB demonstrated that ketosis slowed cyst growth in animal models, leading to the first human trials.
KETO-ADPKD Trial
Status
Completed
Patients
66
Duration
3 months
Published
Nov 2023
The KETO-ADPKD trial (NCT04680780) was the first randomized controlled trial of ketogenic diet in ADPKD patients, led by Roman-Ulrich Mueller at the University of Cologne in collaboration with Thomas Weimbs. Published in Cell Reports Medicine.
Design
66 ADPKD patients were randomized to one of three arms: ketogenic diet (KD), water fasting (WF, 3 days/month), or control (standard diet) for 3 months.
Key Results
Feasibility: 95% of participants found the ketogenic diet feasible; significant ketogenesis was achieved
eGFR improvement: KD group showed +5.5% (creatinine-based) and +13.9% (cystatin-C-based) eGFR improvement while controls declined
Liver volume: Significant reduction in the KD group (-4.73%) vs. control (+2.04%)
Kidney volume: Trend in right direction (KD -0.55% vs. control +0.79%) but NOT statistically significant — likely underpowered and too short
Body composition: -7.2% body weight, -20.5% body fat in KD group
Safety: Only mild, transient "keto-flu" symptoms reported
Limitations
- - Short duration (3 months) — insufficient to detect kidney volume changes
- - Small sample size (66 patients) — underpowered for primary endpoint
- - Open-label design — participants knew their diet assignment
- - eGFR improvements may reflect hemodynamic changes, not structural benefit
RESET-PKD Pilot
A precursor pilot study with 10 ADPKD patients who underwent either a 14-day ketogenic diet or 3-day water fast. Established feasibility and safety.
- Significant liver volume reduction (-7.7%)
- Kidney volume change not significant in this short period
- Confirmed both interventions were safe and feasible in ADPKD patients
KetoCitra & Ketone Supplements
What is KetoCitra?
KetoCitra is classified as a "medical food" (not a drug or supplement) produced by Santa Barbara Nutrients, Inc., co-founded by Thomas Weimbs. It requires medical supervision and contains:
- BHB (beta-hydroxybutyrate) — to promote therapeutic ketosis
- Citrate — to prevent microcrystal formation that may trigger new cysts
- Electrolytes (K, Mg, Ca) — alkaline base load, sodium-free
Ren-Nu Program (Real-World Data, 2026)
Patients
103
Duration
3 months
Program
KetoCitra + keto diet + dietitian
Control group
None
Results:
- eGFR increased 6.3% (P<0.001)
- BMI improved
- Pain reduced, fewer anti-hypertensives needed
Important: This study had no control group and was authored entirely by company employees. These results should be interpreted with caution pending independent replication.
Key Preclinical Evidence
BHB alone recapitulates ketogenic therapy
iScience, 2024
Both D-BHB and L-BHB stereoisomers reduced cyst growth in PKD animal models, implying a signaling mechanism rather than purely metabolic effect.
BHB + Citrate synergistic effect
American Journal of Physiology, 2024
Combination of BHB and citrate at lower doses outperformed either compound alone at higher doses in rat PKD models, suggesting synergistic benefit.
DIPAK Consortium observational data
Nephrology Dialysis Transplantation, 2024
In 521 ADPKD patients, higher endogenous BHB levels predicted 0.33 mL/min/1.73m² better annual eGFR slope (P=0.008). Independent support from the Netherlands.
Time-Restricted Eating
Patients
29
Duration
12 months
Institution
Univ. of Colorado
Published
2025
29 patients were randomized to an 8-hour eating window (time-restricted eating) vs. healthy eating for 12 months, led by Kristen Nowak.
Key finding: Adherence target was not met (60% vs. 75% goal). Both groups lost modest weight. The study concluded that weight and adiposity loss may matter more than eating timing per se.
Key Researchers
Thomas Weimbs, PhD
UC Santa Barbara
Foundational ketosis-PKD research. BHB mechanisms. Co-founder of Santa Barbara Nutrients (KetoCitra).
Roman-Ulrich Mueller, MD
University of Cologne
Led KETO-ADPKD and RESET-PKD clinical trials. First RCTs of ketogenic diet in ADPKD.
Kristen Nowak, PhD
University of Colorado
Time-restricted eating trial. Dietary interventions and metabolic health in ADPKD.
Ron Gansevoort, MD, PhD
Univ. of Groningen (DIPAK Consortium)
Independent observational study linking endogenous BHB levels to better eGFR outcomes in 521 ADPKD patients.
Important Caveats
- Conflict of interest: The majority of ketogenic/BHB/KetoCitra research originates from or is connected to the Weimbs lab / Santa Barbara Nutrients (the company selling KetoCitra)
- No long-term RCT data: The longest ketogenic intervention trial is 12 months (Colorado TRE trial), which had adherence problems
- Kidney volume reduction not proven: The 3-month KETO-ADPKD trial showed a non-significant trend only
- eGFR confounders: Short-term eGFR improvements could be explained by weight loss, hemodynamic changes, or measurement artifacts
- Independent replication needed: The DIPAK observational study provides some support, but most interventional data comes from one research network
The field is rapidly growing (311+ publications on dietary interventions for PKD), and larger, longer trials are expected in the coming years. Always discuss dietary changes with your nephrologist.